Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

DUBLIN, October 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

    Q3 2009 Financial Highlights

                                                               Q3 2009(1)

    Product sales                                        $603 million    -15%

    Product sales from core products(2)                  $532 million    +20%
    Product sales growth from core products at
    constant exchange rates(2)(3)                                        +23%

    Total revenues                                       $667 million    -14%

    Non GAAP operating income                            $134 million    -52%
    US GAAP operating income                              $92 million    -25%
    Non GAAP diluted earnings per ADS                           $0.49    -58%
    US GAAP diluted earnings per ADS                            $0.33  +$0.52

    (1) Figures compare Q3 2009 results with the same period in 2008.

    (2) Core products represent Shire's products excluding ADDERALL XR.

    (3) Sales growth at constant exchange rates ("CER"), which is a Non GAAP
        measure, is calculated after restating Q3 2009 results using Q3 2008
        average foreign exchange rates.

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver excellent growth from its core products, which were up 20% over an exceptionally strong Q3 2008. This performance reflects our transformation in the past few years into a global biopharmaceutical company with a proven differentiated strategy and a balanced portfolio of new products which is protected by strong exclusivity and patent protection.

The growth of our core products and continued pro-active cost management are positioning us well to deliver on our unchanged guidance framework for 2009 and our aspiration of growing sa
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)...  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 3, 2014 at The New York Palace Hotel ... A live webcast of the Company,s presentation is scheduled to ... of the company by Pat Mackin , President and ...
(Date:11/24/2014)... Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today ... in Melbourne, Australia of ... potential treatment of paroxysmal supraventricular tachycardia (PSVT).  The ... was well tolerated at single doses up to ... profile, desirable PK properties including rapid onset, and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
... Calif., Feb. 28, 2011 WaferGen Biosystems, Inc. (OTC ... of state-of-the-art genomic analysis systems, today announced that industry ... Pediatrics at the University of Southern California (USC) Keck ... of WaferGen. "Dr. Triche joined our ...
... ALTO, Calif., Feb. 28, 2011 Varian Medical Systems, Inc. ... entered into a new agreement with Bank of America N.A. ... accelerated share repurchase program.   Under the accelerated ... America N.A. and receive approximately 3.5 million shares, or 85% ...
Cached Medicine Technology:WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 2WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 3WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 4WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 5Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 2Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 3
(Date:11/26/2014)... (HealthDay News) -- Teens prescribed anti-anxiety or sleep ... drugs than other teens, a new study warns. ... substance abuse assessments on teenagers before prescribing these ... and parents don,t realize the abuse potential," said ... University of Michigan School of Nursing. "These drugs ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
(Date:11/24/2014)... November 24, 2014 The Healthy Skin ... reviews of affordable skin care products, recently announced its ... offers readers a wide variety of articles, tips, and ... as organic skincare alternatives. , According to Emily Lataille, ... main content includes thoroughly researched reviews, tips for the ...
(Date:11/24/2014)... 2014 Abington Health is ... has joined The Neurology Group and has been named ... , A graduate of Vinnica Medical University in ... Einstein Medical Center in Philadelphia and completed a fellowship ... Center at Weill Cornell Medical College. Ternopolska is board ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Recently, SweetDressy.com, ... industry, unveiled its new collection of 2014 Evening Dresses. ... now. According to the company’s marketing manager, the special ... http://www.sweetdressy.com/evening-dresses.html for more. , Sweetdressy.com has been working ... pleased to unveil the latest designs. Their new dresses ...
Breaking Medicine News(10 mins):Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
... (October 28, 2010) University of Minnesota Medical School ... a correlation between increased circuit activity in the right ... triggered by post traumatic stress disorder (PTSD). The ... neural activity, its impact and its manifestation is the ...
... News) -- Improving mothers, literacy skills may boost the ... study. U.S. researchers concluded that a mother,s reading ... critical factor influencing her children,s future academic success, even ... neighborhood income. For their study, the researchers examined ...
... American Academy of Pediatrics (AAP) recommends that parents limit combined ... 2 hours per day for preschool-age children. In a ... Pediatrics , researchers found that many children are exposed to ... with 66% exceeding the recommended daily amount. According to ...
... opinion polls, including newly released data, shows that those who ... in 2010 and those who say they intend to vote ... of what they want the future of health reform legislation ... in Congress on this issue. Nearly three-fourths (73%) ...
... Oct. 27 (HealthDay News) -- When it comes to feelings, ... People tend to have worse and more intense views on ... that have already taken place. The observation touches upon ... people apparently take more extreme positions regarding events that have ...
... evolution in action in cancer cells. They show the ... only is cancer genetically different between different patients, but ... has acquired distinct mutations. Effectively, ten different ... tumours. The complexity of pancreatic cancer genetics uncovered in ...
Cached Medicine News:Health News:U of M researchers identify possible key to treating, understanding post-traumatic stress disorder 2Health News:Moms' Literacy Pivotal to Kids' Academic Success 2Health News:New study suggests most preschool-age children exceed daily screen time recommendations 2Health News:Prospective voters and the new health care law 2Health News: Future Seems to Be Viewed More Harshly Than Past 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 3
Transcranil vascular DWL doppler....
... The Nicolet VersaLab ... or line-operated Doppler system ... peripheral vasculature. Crisp, clear ... complemented with a display ...
... The Blackstone Spinal Fixation ... fixation system that provides ... spinal stabilization. It combines ... and stability with a ...
... Equation System incorporates a semi-rigid design that ... is a reduced-volume and top-tightening spinal instrumentation ... fixation that mimics the load distribution of ... to share, not bear, the load). Stabilizes ...
Medicine Products: